State Street Corp Invests $1.19 Million in Rapport Therapeutics (NASDAQ:RAPP)

State Street Corp acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 58,046 shares of the company’s stock, valued at approximately $1,189,000. State Street Corp owned approximately 0.16% of Rapport Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. acquired a new stake in Rapport Therapeutics in the third quarter valued at $1,498,000. Millennium Management LLC purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $2,716,000. Perceptive Advisors LLC acquired a new stake in Rapport Therapeutics in the 2nd quarter valued at about $17,403,000. ARCH Venture Management LLC purchased a new position in Rapport Therapeutics during the 2nd quarter valued at about $86,730,000. Finally, TD Asset Management Inc acquired a new position in Rapport Therapeutics during the second quarter worth about $2,361,000.

Rapport Therapeutics Trading Up 3.7 %

Shares of NASDAQ RAPP opened at $18.39 on Friday. The firm has a 50-day simple moving average of $21.73. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $29.74.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.